All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Experimental Melanoma Vaccine May Shrink Late-Stage Tumors

June 2nd 2011

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

Vemurafenib Leads the Pack in new Melanoma Drugs, Research to be Presented at ASCO

May 31st 2011

Melanoma is now being treated with drugs and new treatment regimes that have shown great promise

Drug Label Overload

May 31st 2011

'Over-warning' or necessary adverse drug event information?

Abiraterone Acetate Improves Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

May 26th 2011

Men with advanced CRPC who were treated with abiraterone acetate plus prednisone/prednisolone had significant improvement in overall survival

Cervical Cancer Screening Using HPV Serotyping

May 25th 2011

While cervical cancer is a rare disease of women within the United States, it remains a global medical problem

FDA Approves Sutent for Pancreatic Cancer

May 23rd 2011

The FDA has approved Sutent (sunitinib) for the treatment of patients with unresectable, locally advanced, or metastatic pancreatic neuroendocrine tumors (pNET)

Watch Out for the Weekend

May 23rd 2011

Weekend hospital admissions linked to higher patient mortality.

Report Forecasts Double-Digit Increase in Cancer Drug Spending

May 20th 2011

The amount of money spent in the United States on oncology drugs is expected to rise from 8% to 15% a year through 2013

FDA Grants Priority Review to Pfizer's Crizotinib

May 19th 2011

Crizotinib was accepted for filing by the FDA and granted Priority Review status

Towards Personalized Medicine in Ovarian Cancer

May 19th 2011

The goal of personalized medicine remains in its infancy as oncologists strive to determine treatments specific to a patient's tumor characteristics

Roche Files Vemurafenib for Regulatory Approval

May 17th 2011

Vemurafenib works by selectively targeting and inhibiting a mutated form of the BRAF protein found in about half of all cases of melanoma

New Information about Fatigue Experienced by Breast Cancer Survivors

May 16th 2011

Higher levels of norepinephrine are found in women with persistent fatigue.

ASTRO Issues Guidelines for Palliative Lung Cancer Care

May 13th 2011

ASTRO has for the first time issued its own extensive guidelines for the use of palliative thoracic radiotherapy in patients with metastatic lung cancer

Four-Drug Chemotherapy Combo Extends Lives of Patients with Pancreatic Cancer

May 12th 2011

Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma

Cancer Cells Outsmarting Smart Bombs: Gastrointestinal Stromal Tumors (GIST)

May 12th 2011

Certain patients whose cancer cells form mutations and build up a resistance to drugs, drive the need for second- and third-line therapies

Oncolytic Viruses Target Pancreatic Stem Cells

May 10th 2011

Oncolytic viruses have the potential of killing cancer stem cells, particularly in cases of potentially fatal pancreatic cancer

Osteosarcoma Survivor Sings Message of Hope

May 9th 2011

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States

Smoking Bans

May 9th 2011

Half of US states currently have anti-smoking laws; the goal is 100%

Revlimid Results for Multiple Myeloma Deemed "Historic"

May 6th 2011

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

FDA Approves Afinitor for Pancreatic Cancer

May 6th 2011

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease